Women and GH secretagogues: why men's data don't transfer
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- Women release growth hormone in more frequent, steadier pulses than men, whose release is dominated by large pulses at night.
- Oral estrogen, including contraceptive pills containing ethinylestradiol, is linked to lower IGF-1 and a weaker response to growth hormone; skin-patch estrogen did not lower IGF-1 in a randomised trial.
- The human studies of ipamorelin and tesamorelin were done mostly or entirely in men, and none reported results for women separately in its abstract or label summary.
- So doses and results from studies of men may not apply to women.
Women and men release growth hormone differently
Growth hormone is released in pulses, and the pattern differs by sex. A 1998 study comparing young men and women found that men had large nocturnal pulses and relatively small ones during the day, while women had more continuous secretion and more frequent pulses of more uniform size (human study) 1. At rest, the nine women in a 1999 study of 18 adults secreted 3.69 times more growth hormone per burst than the nine men, with higher secretion between bursts and a larger total output; exercise raised growth hormone by a similar amount in both sexes (human study) 2.
Age and body weight matter too. In 130 healthy adults spanning five decades, 24-hour pulsatile secretion fell with age and with body mass index, which the authors found the dominant influence; the greater secretion in women was no longer detectable after age 50, and women over 50 had lower IGF-1 than men of similar age (human study) 3. A single fasting growth hormone test, the authors noted, says little about 24-hour secretion 3.
Estrogen changes growth hormone's effect
Estrogen does not just change how much growth hormone is released; it changes what growth hormone does. A 2004 review in Endocrine Reviews explains that oral, but not transdermal, estrogen impairs growth hormone's metabolic action in the liver, lowering IGF-1 production and fat oxidation, which results in a loss of lean tissue and a gain of body fat in postmenopausal women and a weaker effect of growth hormone replacement in women with pituitary failure (review) 4.
A randomised trial in 196 healthy postmenopausal women tested the route directly. Over six months, oral estradiol (1 mg a day, with progesterone) lowered IGF-1 compared with placebo and with transdermal estradiol (50 µg, with progesterone), while transdermal estradiol had no effect; IGF-1 results were available for 133 of the women (randomised trial, secondary analysis) 5. The pill makes a practical difference: in a review of the records of 88 women aged 18 to 47 with growth hormone deficiency at one London clinic, those on contraceptive pills containing ethinylestradiol needed significantly higher growth hormone doses and responded less than women on no estrogen or transdermal estrogen (clinical record review) 6.
Who the secretagogue studies actually included
Against that biology, look at who was studied. Ipamorelin's human pharmacokinetic study gave one 15-minute intravenous infusion to eight healthy men at each of five dose levels (human study) 7. Its one randomised trial, in 114 adults recovering from bowel surgery, did not report results by sex in its abstract and found no significant difference from placebo (phase 2 trial) 8. The tesamorelin trials behind its approval enrolled adults with HIV and lipodystrophy, 84% to 90% of them men across the four study phases (drug label) 9. CJC-1295's 2006 study enrolled healthy adults aged 21 to 61, without separate results by sex in the abstract (human study) 10. An exception was a two-year trial of MK-677 (ibutamoren) in 65 adults aged 60 to 81, which included men, women taking hormone therapy and women not taking it (randomised trial) 11.
| Study | Who was studied |
|---|---|
| Ipamorelin, human pharmacokinetics (1999) | 40 healthy men, eight at each of five doses, one intravenous infusion 7 |
| Ipamorelin, phase 2 trial after bowel surgery (2014) | 114 adults; no results by sex in the abstract 8 |
| CJC-1295 (2006) | Healthy adults aged 21 to 61; no results by sex in the abstract 10 |
| Tesamorelin registration trials (EGRIFTA WR label) | Adults with HIV and lipodystrophy, 84% to 90% men across the four study phases 9 |
| MK-677 (ibutamoren), two-year trial (2008) | 65 adults aged 60 to 81: men, and women with and without hormone therapy 11 |
| Ipamorelin, bone and pituitary studies in rats (2000 to 2002) | Female rats 12 13 14 |
Several of ipamorelin's animal studies were in female rats: bone growth and bone mineral 12, steroid-induced weakness 13 and pituitary growth hormone cells 14. But rat growth hormone patterns are themselves sex-specific 1, and rodent results are not a substitute for human data. When a trial does include women, the useful question is whether it reports results for them separately; the tesamorelin label's study descriptions give the share of men but no results by sex 9.
Do women respond differently? A clue from growth hormone itself
The clearest evidence on sex differences in response comes from growth hormone itself rather than secretagogues. In a 26-week randomised trial in 57 women and 74 men aged 65 to 88, growth hormone raised lean body mass by 1.0 kg in women but 3.1 kg in men, and with added sex hormones by 2.1 kg against 4.3 kg; strength did not rise significantly in either sex except for a marginal gain in men given growth hormone with testosterone (randomised trial) 15. Women responded, but less, and strength did not follow. Fat mass fell in women given growth hormone, with or without hormone therapy, and swelling was more common in women given growth hormone (39% and 38%, against none without it) 15. That was growth hormone itself, injected three times a week in a controlled trial.
A related peptide shows how stark sex differences in hormone responses can be. Kisspeptin-10, which stimulates the reproductive axis, raised LH and FSH in men at low intravenous doses but did not change them in women in the follicular phase of the menstrual cycle even at maximal doses, though it did in women just before ovulation; each group had four or five people (human study) 16. It is a reminder that a peptide's effect in men cannot simply be assumed in women.
Menopause, age and estrogen replacement
Age matters in women apart from estrogen. A study compared eight women with premature menopause, aged 25 to 40, with eight postmenopausal women aged 51 to 70, before and after six to eight weeks of transdermal estradiol. Estradiol raised mean and basal growth hormone in both groups without changing pulse frequency, pulse size or IGF-1, and the younger women secreted significantly more growth hormone than the older women regardless of treatment; the authors concluded that age and body composition, more than moderate estradiol doses, drive growth hormone in women (human study) 17.
That has a practical consequence for anyone comparing their response to someone else's. A woman's age 17, whether she is pre- or postmenopausal, which partly explains IGF-1 differences 3, and whether she uses oral or transdermal estrogen 5 all change her growth hormone and IGF-1.
Blood sugar effects by sex
Raising growth hormone tends to worsen insulin sensitivity, and the details differ by sex. In older adults given growth hormone, women showed higher insulin levels after a glucose drink without higher glucose, while men showed higher glucose and insulin; insulin sensitivity fell in both (randomised trial) 18. In the two-year MK-677 trial, which included women, fasting glucose rose by an average of 0.3 mmol/L on 25 mg a day and insulin sensitivity fell, effects our blood sugar guide covers in detail 11.
What women using these peptides report
A study of 23 discussion threads on nine bodybuilding forums found women using CJC-1295 for weight loss, muscle, youthful skin, sleep and injury healing, usually alongside other performance and image drugs, and worrying about how sex differences in growth hormone pulses affect dosing and cycling and about long-term consequences (qualitative study) 19. The studies above bear out the first worry: the human data on these secretagogues come mostly or entirely from men 7 9.
What this means in practice
Several practical points follow from the evidence. First, a woman's growth hormone pattern and IGF-1 depend on age, weight and whether she takes oral estrogen 3 5. Second, IGF-1, a common yardstick for a secretagogue's effect, is itself lowered by oral estrogen, so it is a poor guide for women on the pill or oral hormone therapy 5 6. Third, growth-hormone-raising compounds affect blood sugar 11 18; our blood sugar guide covers MK-677's effects. Fourth, Drugs@FDA lists no application for ipamorelin, ibutamoren (MK-677) or CJC-1295, so no US label sets a dose for anyone, women included 20.
What a doctor would want to check
For tesamorelin, the one approved growth hormone releasing peptide in this group, the label spells out its monitoring. The EGRIFTA WR label warns that glucose intolerance or diabetes may develop and advises evaluating glucose before and during treatment, advises monitoring IGF-1, warns of fluid retention, and contraindicates use in pregnancy 9. A doctor assessing a woman considering any growth-hormone-raising compound would also want to know her menopausal status and any estrogen she takes, since both change growth hormone and IGF-1 3 5, and would read an IGF-1 result with those in mind 3. Our guide to talking to your doctor about peptides includes a script.
Pregnancy and fertility
The EGRIFTA WR label contraindicates tesamorelin in pregnancy, because modifying visceral fat offers no benefit in pregnancy and could harm the fetus; given to rats during organogenesis, it caused hydrocephaly in offspring (drug label) 9. A PubMed search on October 28, 2026 found no study of ipamorelin, ibutamoren (MK-677) or CJC-1295 in pregnancy or breastfeeding 21. Anyone who is pregnant, trying to conceive or breastfeeding has no human safety data to go on for these three.
Sport
WADA's 2026 Prohibited List names CJC-1295 and tesamorelin among growth hormone-releasing hormone analogues, and ipamorelin and ibutamoren (MK-677) among growth hormone secretagogues, all under S2.2.4 and prohibited at all times, for women and men alike 22. Our WADA hub lists them.
Questions to ask before using a GH peptide
- Was the evidence for this peptide gathered in women at all?
- Am I taking oral estrogen or a combined pill, which changes growth hormone's effect and IGF-1?
- Am I pregnant, planning pregnancy or breastfeeding?
- Do I have blood sugar problems?
- Am I subject to anti-doping rules?
The bottom line
Women's growth hormone system works differently from men's: steadier, more frequent pulses, a sex difference not detectable after 50, and a strong interaction with oral estrogen that lowers IGF-1 and blunts growth hormone's action 1 3 5. The human studies behind ipamorelin and tesamorelin were largely or entirely in men, and in older adults growth hormone itself built less lean mass in women than men 7 9 15. Doses and results from studies of men do not simply transfer.
Frequently asked questions
Do women release growth hormone differently from men?
Yes. Women have more frequent, more uniform growth hormone pulses, while men's release is dominated by large pulses at night. In a study of 130 adults the difference was not detectable after age 50.
Does the birth control pill affect growth hormone?
Oral estrogen lowered IGF-1 in a randomised trial where skin-patch estrogen did not, and women with GH deficiency on pills containing ethinylestradiol needed higher GH doses.
Is ipamorelin studied in women?
Its human pharmacokinetic study used only men. Its phase 2 trial in 114 adults after bowel surgery gave no results by sex in its abstract. Several of its animal studies used female rats, which do not substitute for human data.
Do women respond to growth hormone like men?
In a trial in older adults, growth hormone raised lean mass by 1.0 kg in women against 3.1 kg in men, and strength did not improve significantly in women.
Are GH peptides safe in pregnancy?
Tesamorelin's label contraindicates it in pregnancy. A PubMed search found no pregnancy or breastfeeding study of ipamorelin, MK-677 or CJC-1295.
Related on Grey Peptides
Sources
- Jaffe, C. A., et al. (1998). Regulatory mechanisms of growth hormone secretion are sexually dimorphic. J Clin Invest, 102(1), 153-64. PMID: 9649569
- Wideman, L., et al. (1999). Effects of gender on exercise-induced growth hormone release. J Appl Physiol (1985), 87(3), 1154-62. PMID: 10484590
- Roelfsema, F., et al. (2016). Growth Hormone Dynamics in Healthy Adults Are Related to Age and Sex and Strongly Dependent on Body Mass Index. Neuroendocrinology, 103(3-4), 335-44. PMID: 26228064
- Leung, K. C., et al. (2004). Estrogen regulation of growth hormone action. Endocr Rev, 25(5), 693-721. PMID: 15466938
- Sonnet, E., et al. (2007). Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol (Oxf), 66(5), 626-31. PMID: 17492948
- Phelan, N., et al. (2012). Quantification of the adverse effect of ethinylestradiol containing oral contraceptive pills when used in conjunction with growth hormone replacement in routine practice. Clin Endocrinol (Oxf), 76(5), 729-33. PMID: 22098528
- Gobburu, J. V., et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res, 16(9), 1412-6. PMID: 10496658
- Beck, D. E., et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis, 29(12), 1527-34. PMID: 25331030
- Theratechnologies. EGRIFTA WR (tesamorelin) US prescribing information (revised 3/2025), sections 4, 5.2-5.4, 8.1 and 14 (four study phases in HIV-infected adults with lipodystrophy, 86%, 84%, 88% and 90% male). DailyMed set 839334d3, version 2 (updated July 29, 2026); re-read October 28, 2026. DailyMed
- Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799-805. PMID: 16352683
- Nass, R., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med, 149(9), 601-11. PMID: 18981485
- Svensson, J., et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol, 165(3), 569-77. PMID: 10828840
- Andersen, N. B., et al. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res, 11(5), 266-72. PMID: 11735244
- Jiménez-Reina, L., et al. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol, 17(3), 707-14. PMID: 12168778
- Blackman, M. R., et al. (2002). Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA, 288(18), 2282-92. PMID: 12425705
- Jayasena, C. N., et al. (2011). The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab, 96(12), E1963-72. PMID: 21976724
- Lieman, H. J., et al. (2001). Effects of aging and estradiol supplementation on GH axis dynamics in women. J Clin Endocrinol Metab, 86(8), 3918-23. PMID: 11502833
- Münzer, T., et al. (2009). Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men. J Clin Endocrinol Metab, 94(10), 3833-41. PMID: 19602554
- Van Hout, M. C., et al. (2016). Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse, 51(1), 73-84. PMID: 26771670
- FDA. Drugs@FDA via openFDA: no application for ipamorelin, ibutamoren or CJC-1295; tesamorelin, BLA 022505 (EGRIFTA), Theratechnologies, original approval November 10, 2010. Searched October 28, 2026.
- PubMed search, October 28, 2026: (ipamorelin OR ibutamoren OR MK-677 OR MK-0677 OR CJC-1295) AND (pregnancy OR pregnant OR lactation OR breastfeeding); 0 records.
- World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S2.2.4 (growth hormone releasing factors) names CJC-1295 and tesamorelin (GHRH analogues) and ibutamoren (MK-677) and ipamorelin (GH secretagogues); prohibited at all times. Read October 28, 2026. WADA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead